146 research outputs found
First measurements with a new -electron detector for spectral shape studies
The shape of the spectrum corresponding to the electrons emitted in
decay carries a wealth of information about nuclear structure and fundamental
physics. In spite of that, few dedicated measurements have been made of
-spectrum shapes. In this work we present a newly developed detector for
electrons based on a telescope concept. A thick plastic scintillator is
employed in coincidence with a thin silicon detector. First measurements
employing this detector have been carried out with mono-energetic electrons
from the high-energy resolution electron-beam spectrometer at Bordeaux. Here we
report on the good reproduction of the experimental spectra of mono-energetic
electrons using Monte Carlo simulations. This is a crucial step for future
experiments, where a detailed Monte Carlo characterization of the detector is
needed to determine the shape of the -electron spectra by deconvolution
of the measured spectra with the response function of the detector. A chamber
to contain two telescope assemblies has been designed for future -decay
experiments at the Ion Guide Isotope Separator On-Line facility in
Jyv\"askyl\"a, aimed at improving our understanding of reactor antineutrino
spectra
The STAR Silicon Strip Detector (SSD)
The STAR Silicon Strip Detector (SSD) completes the three layers of the
Silicon Vertex Tracker (SVT) to make an inner tracking system located inside
the Time Projection Chamber (TPC). This additional fourth layer provides two
dimensional hit position and energy loss measurements for charged particles,
improving the extrapolation of TPC tracks through SVT hits. To match the high
multiplicity of central Au+Au collisions at RHIC the double sided silicon strip
technology was chosen which makes the SSD a half million channels detector.
Dedicated electronics have been designed for both readout and control. Also a
novel technique of bonding, the Tape Automated Bonding (TAB), was used to
fullfill the large number of bounds to be done. All aspects of the SSD are
shortly described here and test performances of produced detection modules as
well as simulated results on hit reconstruction are given.Comment: 11 pages, 8 figures, 1 tabl
Online Monitoring of the Osiris Reactor with the Nucifer Neutrino Detector
Originally designed as a new nuclear reactor monitoring device, the Nucifer
detector has successfully detected its first neutrinos. We provide the second
shortest baseline measurement of the reactor neutrino flux. The detection of
electron antineutrinos emitted in the decay chains of the fission products,
combined with reactor core simulations, provides an new tool to assess both the
thermal power and the fissile content of the whole nuclear core and could be
used by the Inter- national Agency for Atomic Energy (IAEA) to enhance the
Safeguards of civil nuclear reactors. Deployed at only 7.2m away from the
compact Osiris research reactor core (70MW) operating at the Saclay research
centre of the French Alternative Energies and Atomic Energy Commission (CEA),
the experiment also exhibits a well-suited configuration to search for a new
short baseline oscillation. We report the first results of the Nucifer
experiment, describing the performances of the 0.85m3 detector remotely
operating at a shallow depth equivalent to 12m of water and under intense
background radiation conditions. Based on 145 (106) days of data with reactor
ON (OFF), leading to the detection of an estimated 40760 electron
antineutrinos, the mean number of detected antineutrinos is 281 +- 7(stat) +-
18(syst) electron antineutrinos/day, in agreement with the prediction 277(23)
electron antineutrinos/day. Due the the large background no conclusive results
on the existence of light sterile neutrinos could be derived, however. As a
first societal application we quantify how antineutrinos could be used for the
Plutonium Management and Disposition Agreement.Comment: 22 pages, 16 figures - Version
Periodontal treatment to improve glycaemic control in diabetic patients: study protocol of the randomized, controlled DIAPERIO trial
<p>Abstract</p> <p>Background</p> <p>Periodontitis is a common, chronic inflammatory disease caused by gram-negative bacteria leading to destruction of tissues supporting the teeth. Epidemiological studies have consistently shown increased frequency, extent and severity of periodontitis among diabetic adults. More recently, some controlled clinical trials have also suggested that periodontal treatment could improve glycaemic control in diabetic patients. However current evidence does not provide sufficient information on which to confidently base any clinical recommendations. The main objective of this clinical trial is to assess whether periodontal treatment could lead to a decrease in glycated haemoglobin levels in metabolically unbalanced diabetic patients suffering from chronic periodontitis.</p> <p>Methods</p> <p>The DIAPERIO trial is an open-label, 13-week follow-up, randomized, controlled trial. The total target sample size is planned at 150 participants, with a balanced (1:1) treatment allocation (immediate treatment vs delayed treatment). Periodontal treatment will include full mouth non-surgical scaling and root planing, systemic antibiotherapy, local antiseptics (chlorhexidine 0.12%) and oral health instructions. The primary outcome will be the difference in change of HbA1c between the two groups after the 13-weeks' follow-up. Secondary outcomes will be the difference in change of fructosamine levels and quality of life between the two groups.</p> <p>Discussion</p> <p>The DIAPERIO trial will provide insight into the question of whether periodontal treatment could lead to an improvement in glycaemic control in metabolically unbalanced diabetic patients suffering from periodontitis. The results of this trial will help to provide evidence-based recommendations for clinicians and a draft framework for designing national health policies.</p> <p>Trial registration</p> <p>Current Controlled Trials ISRCTN15334496</p
Bone Mass and Strength in Older Men With Type 2 Diabetes: The Osteoporotic Fractures in Men Study
The effects of type 2 diabetes mellitus (T2DM) on bone volumetric density, bone geometry, and estimates of bone strength are not well established. We used peripheral quantitative computed tomography (pQCT) to compare tibial and radial bone volumetric density (vBMD, mg/cm3), total (ToA, mm2) and cortical (CoA, mm2) bone area and estimates of bone compressive and bending strength in a subset (n = 1171) of men (≥65 years of age) who participated in the multisite Osteoporotic Fractures in Men (MrOS) study. Analysis of covariance–adjusted bone data for clinic site, age, and limb length (model 1) and further adjusted for body weight (model 2) were used to compare data between participants with (n = 190) and without (n = 981) T2DM. At both the distal tibia and radius, patients with T2DM had greater bone vBMD (+2% to +4%, model 1, p < .05) and a smaller bone area (ToA −1% to −4%, model 2, p < .05). The higher vBMD compensated for lower bone area, resulting in no differences in estimated compressive bone strength at the distal trabecular bone regions. At the mostly cortical bone midshaft sites of the radius and tibia, men with T2DM had lower ToA (−1% to −3%, p < .05), resulting in lower bone bending strength at both sites after adjusting for body weight (−2% to −5%, p < .05) despite the lack of difference in cortical vBMD at these sites. These data demonstrate that older men with T2DM have bone strength that is low relative to body weight at the cortical-rich midshaft of the radius despite no difference in cortical vBMD. © 2010 American Society for Bone and Mineral Researc
Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area
Background: Kidney disease is associated with an increased total mortality and cardiovascular morbimortality in the general population and in patients with Type 2 diabetes. The aim of this study is to determine the prevalence of kidney disease and different types of renal disease in patients with type 2 diabetes (T2DM). Methods: Cross-sectional study in a random sample of 2,642 T2DM patients cared for in primary care during 2007. Studied variables: demographic and clinical characteristics, pharmacological treatments and T2DM complications (diabetic foot, retinopathy, coronary heart disease and stroke). Variables of renal function were defined as follows: 1) Microalbuminuria: albumin excretion rate & 30 mg/g or 3.5 mg/mmol, 2) Macroalbuminuria: albumin excretion rate & 300 mg/g or 35 mg/mmol, 3) Kidney disease (KD): glomerular filtration rate according to Modification of Diet in Renal Disease < 60 ml/min/1.73 m2 and/or the presence of albuminuria, 4) Renal impairment (RI): glomerular filtration rate < 60 ml/min/1.73 m2, 5) Nonalbuminuric RI: glomerular filtration rate < 60 ml/min/1.73 m2 without albuminuria and, 5) Diabetic nephropathy (DN): macroalbuminuria or microalbuminuria plus diabetic retinopathy. Results: The prevalence of different types of renal disease in patients was: 34.1% KD, 22.9% RI, 19.5% albuminuria and 16.4% diabetic nephropathy (DN). The prevalence of albuminuria without RI (13.5%) and nonalbuminuric RI (14.7%) was similar. After adjusting per age, BMI, cholesterol, blood pressure and macrovascular disease, RI was significantly associated with the female gender (OR 2.20; CI 95% 1.86-2.59), microvascular disease (OR 2.14; CI 95% 1.8-2.54) and insulin treatment (OR 1.82; CI 95% 1.39-2.38), and inversely associated with HbA1c (OR 0.85 for every 1% increase; CI 95% 0.80-0.91). Albuminuria without RI was inversely associated with the female gender (OR 0.27; CI 95% 0.21-0.35), duration of diabetes (OR 0.94 per year; CI 95% 0.91-0.97) and directly associated with HbA1c (OR 1.19 for every 1% increase; CI 95% 1.09-1.3). Conclusions: One-third of the sample population in this study has KD. The presence or absence of albuminuria identifies two subgroups with different characteristics related to gender, the duration of diabetes and metabolic status of the patient. It is important to determine both albuminuria and GFR estimation to diagnose KD
Cardiovasc Diabetol
BACKGROUND: Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an association between SAF and major adverse cardiovascular events (MACE) incidence in subjects with Type 1 Diabetes (T1D) during a 7 year follow-up. METHODS: During year 2009, 232 subjects with T1D were included. SAF measurement, clinical [age, sex, body mass index (BMI), comorbidities] and biological data (HbA1C, blood lipids, renal parameters) were recorded. MACE (myocardial infarction, stroke, lower extremity amputation or a revascularization procedure) were registered at visits in the center or by phone call to general practitioners until 2016. RESULTS: The participants were mainly men (59.5%), 51.5 +/- 16.7 years old, with BMI 25.0 +/- 4.1 kg/m(2), diabetes duration 21.5 +/- 13.6 years, HbA1C 7.6 +/- 1.1%. LDL cholesterol was 1.04 +/- 0.29 g/L, estimated Glomerular Filtration Rates (CKD-EPI): 86.3 +/- 26.6 ml/min/1.73 m(2). Among these subjects, 25.1% were smokers, 45.3% had arterial hypertension, 15.9% had elevated AER (>/= 30 mg/24 h), and 9.9% subjects had a history of previous MACE. From 2009 to 2016, 22 patients had at least one new MACE: 6 myocardial infarctions, 1 lower limb amputation, 15 revascularization procedures. Their SAF was 2.63 +/- 0.73 arbitrary units (AU) vs 2.08 +/- 0.54 for other patients (p = 0.002). Using Cox-model, after adjustment for age (as the scale time), sex, diabetes duration, BMI, hypertension, smoking status, albumin excretion rates, statin treatment and a previous history of MACE, higher baseline levels of SAF were significantly associated with an increased risk of MACE during follow-up (HR = 4.13 [1.30-13.07]; p = 0.02 for 1 AU of SAF) and Kaplan-Meier curve follow-up showed significantly more frequent MACE in group with SAF upper the median (p = 0.001). CONCLUSION: A high SAF predicts MACE in patients with T1D
- …